News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Effect of InterMune, Inc.'s (JOBS) Lung Drug, Pirfenidone Unclear; Shares Soar Despite FDA Concerns
March 5, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. health regulatory staff are concerned that studies of InterMune Inc's (ITMN.O) drug to treat lung scarring may not be enough to prove the treatment works and may point to safety issues, according to documents made public on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Vaccines
CDC’s Vaccine Committee Recommends Delaying Hepatitis B Birth Dose
December 5, 2025
·
3 min read
·
Tristan Manalac
Huntington’s disease
FDA Minutes Confirm Challenging Path Ahead for UniQure’s Huntington’s Gene Therapy
December 4, 2025
·
2 min read
·
Heather McKenzie
Vaccines
Former CDC, FDA Chiefs Decry Vaccine Policy Changes as ACIP Meeting Begins
December 4, 2025
·
2 min read
·
Dan Samorodnitsky
Policy
FDA Eyes Higher User Fees for Companies Holding Phase I Studies Abroad
December 4, 2025
·
2 min read
·
Tristan Manalac